Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
The government unveiled a draft of its economic and fiscal policy guidelines on June 22, which included, alongside a new generic penetration target of 80%, measures to ensure the stable supply of essential medicines and propel innovation in the drug…
To read the full story
Related Article
- Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…